KNBWY
Kirin Holdings Company, Limited
Set alert
18.36 USD +0.36 +2.00%
18.37 Day range 18.91
14.01 52-week range 19.99
- YTD
- +21.91%
- 1 year
- +29.30%
- Open
- 18.91
- Prev close
- 18.00
- Mkt cap
- 14.51B
- Vol
- 1.90K
- Avg vol
- 22.98K
- EPS
- 1.57
- P/E
- 11.69
More statistics
- Low
- 18.37
- High
- 18.91
- Earnings
- Aug 6, 2026
Next earnings
Aug 6, 2026
Expected Aug 6, 2026. Consensus EPS estimate 0.4792.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 6, 2026 | Jun 30, 2026 | 0.4792 | — | — | — |
| May 14, 2026 | Mar 31, 2026 | 0.26 | 0.21 | -0.05 | -19.23% |
| Feb 13, 2026 | Dec 31, 2025 | 0.4133 | 0.36 | -0.05 | -12.90% |
| Nov 11, 2025 | Sep 30, 2025 | 0.34 | 0.42 | +0.08 | +23.53% |
| Aug 7, 2025 | Jun 30, 2025 | 0.28 | 0.24 | -0.04 | -14.29% |
| May 13, 2025 | Mar 31, 2025 | 0.2126 | 0.20 | -0.01 | -5.93% |
News
- Kirin (KNBWY) is an Incredible Growth Stock: 3 Reasons Why
- Are Investors Undervaluing Kirin (KNBWY) Right Now?
- Arcadia Biosciences (NASDAQ:RKDA) and Kirin (OTCMKTS:KNBWY) Financial Survey
- The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
- Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
- Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
- Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
- Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
- Kyowa Kirin stops development of skin condition treatment
Your note
Sign in to keep a note on KNBWY — it syncs with the Stock Master app.